Efficacy of repetitive transcranial magnetic stimulation in cognitive impairment of neurodegenerative diseases: a systematic review and meta-analysis.

This study reviewed research on repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, for treating cognitive problems and emotional symptoms in people with Alzheimer's disease and Parkinson's disease. Researchers analyzed 17 randomized controlled trials involving patients with these neurodegenerative conditions. The study focused on whether stimulating different brain areas, particularly the dorsolateral prefrontal cortex (DLPFC), could improve thinking abilities, mood, and daily functioning.

The results showed that rTMS had positive effects on cognitive function, with improvements measured on standard mental assessment tests like the Montreal Cognitive Assessment and Mini-Mental State Examination. Patients also experienced reduced anxiety symptoms. The treatment appeared most effective when targeting the DLPFC region of the brain. However, effects on depression and daily living activities were less clear.

What this means for patients: While this research is promising for brain stimulation therapy, it's important to note this study did not involve acupuncture. However, acupuncture may offer complementary benefits for patients with neurodegenerative diseases. Some research suggests acupuncture can help with cognitive symptoms, mood disorders, and quality of life in Alzheimer's and Parkinson's patients. Like rTMS, acupuncture may influence brain function and neural pathways, though through different mechanisms. The combination of conventional medical care with integrative approaches like acupuncture may provide additional support for managing these complex conditions. If you're considering acupuncture for cognitive or neurological concerns, seek care from a licensed acupuncturist experienced in treating neurodegenerative conditions.

This systematic review and meta-analysis evaluated rTMS efficacy for cognitive and emotional symptoms in Alzheimer's disease and Parkinson's disease patients. Seventeen RCTs were analyzed from five databases, with treatment effects assessed using standardized measures (MoCA, MMSE, HAMD, HAMA, ADL). Pooled results demonstrated significant improvements: MoCA (MD: 2.13, 95% CI [0.75, 3.52], p<0.001), MMSE (MD: 1.16, 95% CI [0.91, 1.41], p=0.0075), and HAMA (SMD: -0.62, 95% CI [-0.91, -0.33], p<0.001). HAMD and ADL showed non-significant effects. Heterogeneity analysis revealed significant differences in MoCA scores between DLPFC and non-DLPFC targets, with DLPFC demonstrating superior outcomes. Clinical implications suggest DLPFC as an optimal target for addressing non-motor neurodegenerative symptoms. While acupuncture practitioners may not directly apply these findings, understanding the neuroplasticity mechanisms underlying cognitive improvement in neurodegenerative diseases informs integrative treatment planning. Consider referral for rTMS evaluation when treating patients with cognitive impairment from neurodegenerative conditions.